Immunic reports positive Phase 2 CALLIPER interim data: NfL reduced 22.4% vs placebo in PMS

IMMUNIC, INC.

Vidofludimus calcium lowered serum NfL by 22.4% vs placebo at 24 weeks in overall PMS (p=0.01 post hoc).
Non-active SPMS subgroup showed 20.1% NfL reduction; PPMS showed 18.8% reduction.
GFAP increased 3.7% for drug vs 4.4% for placebo at 24 weeks; 2.7% vs 6.4% at 48 weeks.
Top-line CALLIPER data expected April 2025; Phase 3 ENSURE interim data late 2024.
NfL reduction numerically higher than historical Ocrevus data in PPMS (22.4% vs 12.4%).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.